S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
All the trading advice you’ve ever received boils down to this (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
All the trading advice you’ve ever received boils down to this (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
All the trading advice you’ve ever received boils down to this (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
All the trading advice you’ve ever received boils down to this (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
All the trading advice you’ve ever received boils down to this (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
All the trading advice you’ve ever received boils down to this (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
All the trading advice you’ve ever received boils down to this (Ad)
Federal Trade Commission is investigating ExxonMobil's $60B deal to acquire a Texas oil company
Zuckerberg sells Meta, Snowflake may be the better choice
All the trading advice you’ve ever received boils down to this (Ad)
Grab Starbucks on the dip before coffee futures fall
GM rally picks up steam after landing full bull rating

Altamira Therapeutics Stock Price, News & Analysis (NASDAQ:CYTO)

$0.44
+0.08 (+20.88%)
(As of 09:04 AM ET)
Compare
Today's Range
$0.44
$0.44
50-Day Range
$0.10
$0.64
52-Week Range
$0.09
$5.99
Volume
4.86 million shs
Average Volume
4.48 million shs
Market Capitalization
$3.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CYTO stock logo

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.

CYTO Stock Price History

CYTO Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Trending tickers: Microsoft | Bitcoin | Altamira | Ashtead
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
See More Headlines
Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTO
Employees
16
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$120,287.00
Book Value
($7.38) per share

Miscellaneous

Free Float
6,078,000
Market Cap
$2.53 million
Optionable
Not Optionable
Beta
1.69
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Thomas Meyer Ph.D. (Age 55)
    Founder, Chairman, CEO & MD
    Comp: $566.88k
  • Mr. Marcel Gremaud CPA (Age 65)
    Chief Financial Officer
  • Dr. Covadonga Paneda (Age 49)
    Chief Operating Officer
  • Dr. Samuel A. Wickline M.D. (Age 70)
    Chief Scientific Adviser














CYTO Stock Analysis - Frequently Asked Questions

How have CYTO shares performed in 2023?

Altamira Therapeutics' stock was trading at $4.85 at the beginning of 2023. Since then, CYTO stock has decreased by 92.5% and is now trading at $0.3620.
View the best growth stocks for 2023 here
.

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average daily trading volume, of 8,950,000 shares, the days-to-cover ratio is presently 0.1 days.
View Altamira Therapeutics' Short Interest
.

When did Altamira Therapeutics' stock split?

Altamira Therapeutics shares reverse split before market open on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Altamira Therapeutics' major shareholders?

Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTO) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -